Providence Therapeutics Submits Clinical Trial Application (CTA) to Health Canada for its mRNA COVID Vaccine
CALGARY, AB, Dec. 4, 2020 /CNW/ - Providence Therapeutics confirmed today that a Clinical Trial Application (CTA) was submitted to Health Canada, December 3, for the mRNA COVID vaccine, PTX-COVID19-B. The company has been keeping Health Canada informed through development of the vaccine candidate.
The Company will not comment further until appropriate discussions have been concluded with Health Canada.
For more information, please visit www.providencetherapeutics.com.